CN112386575A - 一种代谢调节融合蛋白的冻干制剂 - Google Patents
一种代谢调节融合蛋白的冻干制剂 Download PDFInfo
- Publication number
- CN112386575A CN112386575A CN201910763612.9A CN201910763612A CN112386575A CN 112386575 A CN112386575 A CN 112386575A CN 201910763612 A CN201910763612 A CN 201910763612A CN 112386575 A CN112386575 A CN 112386575A
- Authority
- CN
- China
- Prior art keywords
- freeze
- fusion protein
- drying
- fgf21
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
样品 | T<sub>m onset</sub>/℃ | T<sub>m1</sub>/℃ | T<sub>m2</sub>/℃ |
实施例1 | 45.95 | 70.09 | 84.56 |
实施例2 | 45.57 | 69.43 | 84.06 |
实施例3 | 44.86 | 68.94 | 83.44 |
实施例4 | 44.41 | 68.42 | 82.89 |
实施例5 | 44.06 | 67.99 | 82.43 |
实施例6 | 43.78 | 67.47 | 81.96 |
实施例7 | 43.59 | 67.11 | 81.73 |
实施例8 | 43.21 | 66.65 | 81.29 |
实施例9 | 42.00 | 65.26 | 79.79 |
实施例10 | 42.88 | 66.16 | 80.76 |
实施例11 | 42.46 | 65.73 | 80.27 |
实施例12 | 41.54 | 64.89 | 79.21 |
实施例13 | 41.03 | 64.21 | 78.75 |
对比实施例1 | 36.31 | 58.76 | 74.98 |
对比实施例2 | 35.20 | 57.43 | 74.11 |
对比实施例3 | 37.64 | 61.21 | 76.49 |
对比实施例4 | 36.76 | 60.07 | 75.71 |
对比实施例5 | 34.19 | 56.19 | 73.28 |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910763612.9A CN112386575B (zh) | 2019-08-19 | 2019-08-19 | 一种代谢调节融合蛋白的冻干制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910763612.9A CN112386575B (zh) | 2019-08-19 | 2019-08-19 | 一种代谢调节融合蛋白的冻干制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112386575A true CN112386575A (zh) | 2021-02-23 |
CN112386575B CN112386575B (zh) | 2023-03-21 |
Family
ID=74603384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910763612.9A Active CN112386575B (zh) | 2019-08-19 | 2019-08-19 | 一种代谢调节融合蛋白的冻干制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112386575B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114015758A (zh) * | 2021-10-15 | 2022-02-08 | 无锡百泰克生物技术有限公司 | 一种冻干保护剂、荧光pcr检测试剂盒及冻干工艺 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011134979A2 (en) * | 2010-04-27 | 2011-11-03 | Scil Technology Gmbh | Stable mia/cd-rap formulation |
CN102670522A (zh) * | 2011-03-16 | 2012-09-19 | 江苏泰康生物医药有限公司 | 含有重组人血清白蛋白-人粒细胞集落刺激因子融合蛋白的药物制剂及其制备 |
CN103945871A (zh) * | 2011-09-26 | 2014-07-23 | 诺华股份有限公司 | 用于治疗代谢疾病的融合蛋白 |
US20160228371A1 (en) * | 2013-10-18 | 2016-08-11 | Abbvie Inc. | Stable solid units and methods of making the same |
CN107088224A (zh) * | 2017-02-10 | 2017-08-25 | 温州医科大学 | 人fgf21冻干制剂 |
CN107108711A (zh) * | 2014-10-23 | 2017-08-29 | 恩格姆生物制药公司 | 包含肽变异体的药物组合物及其使用方法 |
JP2019043961A (ja) * | 2010-04-20 | 2019-03-22 | オクタファルマ・アーゲー | 医薬タンパク質の新規な安定化剤 |
-
2019
- 2019-08-19 CN CN201910763612.9A patent/CN112386575B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019043961A (ja) * | 2010-04-20 | 2019-03-22 | オクタファルマ・アーゲー | 医薬タンパク質の新規な安定化剤 |
WO2011134979A2 (en) * | 2010-04-27 | 2011-11-03 | Scil Technology Gmbh | Stable mia/cd-rap formulation |
CN102869679A (zh) * | 2010-04-27 | 2013-01-09 | Scil技术股份有限公司 | 稳定的水性mia/cd-rap制剂 |
CN102670522A (zh) * | 2011-03-16 | 2012-09-19 | 江苏泰康生物医药有限公司 | 含有重组人血清白蛋白-人粒细胞集落刺激因子融合蛋白的药物制剂及其制备 |
CN103945871A (zh) * | 2011-09-26 | 2014-07-23 | 诺华股份有限公司 | 用于治疗代谢疾病的融合蛋白 |
US20160228371A1 (en) * | 2013-10-18 | 2016-08-11 | Abbvie Inc. | Stable solid units and methods of making the same |
CN107108711A (zh) * | 2014-10-23 | 2017-08-29 | 恩格姆生物制药公司 | 包含肽变异体的药物组合物及其使用方法 |
CN107088224A (zh) * | 2017-02-10 | 2017-08-25 | 温州医科大学 | 人fgf21冻干制剂 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114015758A (zh) * | 2021-10-15 | 2022-02-08 | 无锡百泰克生物技术有限公司 | 一种冻干保护剂、荧光pcr检测试剂盒及冻干工艺 |
Also Published As
Publication number | Publication date |
---|---|
CN112386575B (zh) | 2023-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007261536B2 (en) | VEGF antagonist formulations suitable for intravitreal administration | |
Garidel et al. | Stability of buffer-free freeze-dried formulations: A feasibility study of a monoclonal antibody at high protein concentrations | |
CN108379561B (zh) | 一种聚乙二醇化尿酸氧化酶冻干粉剂及其制备方法 | |
KR20180124120A (ko) | 재조합 산 알파-글루코시다제를 포함하는 제형 | |
CN112386575B (zh) | 一种代谢调节融合蛋白的冻干制剂 | |
Awotwe-Otoo et al. | Product and process understanding to relate the effect of freezing method on glycation and aggregation of lyophilized monoclonal antibody formulations | |
CN113382714A (zh) | 胶原酶制剂及其制备方法 | |
CN112137967B (zh) | 一种重组人FGF21-Fc融合蛋白冻干制剂 | |
CN111195234B (zh) | 一种重组FGF21-Fc融合蛋白冻干粉制剂 | |
US20200023075A1 (en) | Lyophilized pharmaceutical compositions for naked dna gene therapy | |
CN101224296A (zh) | 一种稳定的重组人血管内皮抑制素制剂及其制备工艺 | |
EP4059512A1 (en) | Aqueous pharmaceutical composition containing fusion protein of serum albumin and growth hormone | |
CN113117071B (zh) | 一种无糖基化抗pd-1单克隆抗体的冻干制剂 | |
CN112516090B (zh) | 抗体偶联药物的药物组合、冷冻干燥剂及制备方法、用途 | |
WO2006001240A1 (ja) | 安定化改変ダニ主要アレルゲン含有医薬組成物 | |
CN116829172A (zh) | 一种稳定利拉鲁肽药物制剂的处理方法 | |
Krieg et al. | Overcoming challenges in co-formulation of proteins with contradicting stability profiles-EPO plus G-CSF | |
CN111195349B (zh) | 一种代谢调节融合蛋白的冻干粉制剂 | |
CN116077649A (zh) | 一种含抗Blys单克隆抗体冻干制剂及其制备工艺 | |
CN116549403A (zh) | 卵泡刺激素冻干制剂及其制备方法和用途 | |
ES2882106T3 (es) | Composición de factor de crecimiento nervioso y polvo para inyección | |
CN111228225B (zh) | 一种重组人肿瘤坏死因子受体-Fc融合蛋白冻干制剂 | |
CN108210890A (zh) | 重组人胰高血糖素样肽-1类似物融合蛋白的新型稳定制剂 | |
AU629549B2 (en) | Homogeneous dimeric m-csf and storage stable formulations thereof | |
CN113368063A (zh) | 一种注射用重组白细胞抑制因子和水蛭肽嵌合蛋白冻干制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20210223 Assignee: Anyuan Pharmaceutical Technology (Shanghai) Co.,Ltd. Assignor: LUNAN PHARMACEUTICAL Group Corp. Contract record no.: X2022980011035 Denomination of invention: A lyophilized preparation of metabolic regulation fusion protein License type: Common License Record date: 20220725 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20210223 Assignee: NANJING SHUNXIN PHARMACEUTICALS CO., LTD. OF CHIATAI TIANQING PHARMACEUTICAL Group Assignor: Anyuan Pharmaceutical Technology (Shanghai) Co.,Ltd. Contract record no.: X2022310000141 Denomination of invention: Lyophilized preparation of fusion protein for metabolic regulation License type: General license|Sublicense Record date: 20220929 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
GR01 | Patent grant | ||
GR01 | Patent grant |